Over 2022 the group has made significant contributions towards understanding gene silencing by promoter methylation in colorectal cancer, which significantly contributes to the oncogenic process by restricting the expression of tumor suppressor genes. We have deepened our knowledge on the role of Myosin Vb and RhoA in colorectal and gastric cancer, respectively. We have engineered a conditional and inducible mouse model recapitulating the human syndrome, which is currently being used for testing the efficacy of novel therapies. The laboratory is also involved in the development of cancer therapies using nanosystems.

Group Leader
Diego Arango del Corro

Águeda Martínez Barriocanal

PhD Students
Estefanía Anguita Espinosa, Li Jing, Bruno Brotons Morales

Lab Technicians
Mariona Dalmau Längst










Luk IY, Jenkins LJ, Schoffer KL, Ng I, Tse JWT, Mouradov D, Kaczmarczyk S, Nightingale R, Burrows AD, Anderson RL, Arango D, Dopeso H, Croft L, Richardson MF, Sieber OM, Liao Y, Mooi JK, Vukelic N, Reehorst CM, Afshar-Sterle S, et al.
Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression.
Cell Death Differ. 2022 Nov;29(11):2288-2302.
DOI: doi: 10.1038/s41418-022-01016-w
IF: 12.073

Carton-Garcia F, Brotons B, Anguita E, Dopeso H, Tarragona J, Nieto R, Garcia-Vidal E, Macaya I, Zagyva Z, Dalmau M, Sanchez-Martin M, van Ijzendoorn SCD, Landolfi S, Hernandez-Losa J, Schwartz S Jr, Matias-Guiu X, Ramon Y Cajal S, Martinez-Barriocanal, Arango D.
Myosin Vb as a tumor suppressor gene in intestinal cancer
Oncogene. 2022 Dec;41(49):5279-5288.
DOI: doi: 10.1038/s41388-022-02508-2
IF: 8.756

Fourniols T, Maggio V, Rafael D, Colaco A, Garcia Vidal E, Lopes A, Schwartz S, Martinez-Barriocanal, Preat V, Arango D.
Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation
Eur J Pharm Biopharm. 2022 Feb;171:39-49.
DOI: doi: 10.1016/j.ejpb.2021.10.017
IF: 5.589

RHOA signaling in gastric cancer: friend or foe?
Principal Investigator: Diego Arango del Corro
Agency: Asociación Española Contra el Cáncer
Funding: 1,015,000€
Period: 2015-2022

Cell-penetrating peptides
Priority Number: EP20382968
Priority Date: 10/11/2020
Applicants: VHIR, CIBER